Application of YAP / TAZ inhibitor-2 in the preparation of drugs for preventing and / or treating corneal diseases caused by pathogenic microorganism infection
By using YAP/TAZ inhibitor-2 and its derivatives to activate the gene expression of corneal epithelial cells, and combined with anti-corneal injury, anti-inflammatory and anti-pathogenic microbial drugs, the difficulty of prior art in inhibiting pathogenic microbial infection and restoring the cornea is solved. The problem of epithelial function has achieved effective treatment of corneal diseases and recovery of corneal function.
Patent Information
- Application Number
- CN202410254561.8
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-03-06
- Publication Date
- 2024-11-29
- Estimated Expiration
- 2044-03-06
AI Technical Summary
The prior art is difficult to simultaneously and efficiently inhibit the immune response caused by pathogenic microbial infection and restore corneal epithelial function and characteristics, and is used to treat infectious corneal diseases.
Using YAP/TAZ inhibitor-2 and its derivatives, it promotes corneal epithelial cell differentiation by activating the expression of corneal epithelial cell characteristics, combined with anti-corneal injury, anti-inflammatory and anti-pathogenic microbial drugs, for the preparation of prevention and/or Treatment of corneal diseases caused by pathogenic microbial infection.
YAP/TAZ inhibitor-2 can effectively resist corneal damage caused by pathogenic microorganisms, restore the function and characteristics of the corneal epithelium, relieve corneal epithelial cell lesions, maintain the transparency and integrity of the cornea, and have no obvious drug toxicity.
Smart Images

Figure CN118141811B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedicine technology, and in particular to the use of YAP / TAZ inhibitor-2 in the preparation of drugs for preventing and / or treating corneal diseases caused by pathogenic microorganism infection. Background Art
[0002] Infectious corneal disease refers to inflammation and tissue lesions caused by infection of the cornea by pathogens such as viruses, fungi or bacteria. The superficial layer of the cornea is rich in trigeminal nerve endings, so the disease often has obvious irritation symptoms, such as photophobia, tearing, soreness, etc. Infectious keratitis generally occurs along the trigeminal nerve, and the lesion site invades deeper, and its sensation is reduced, but because the inflammation stimulates the adjacent tissues of the corneal lesions, the irritation symptoms are still obvious. Viral keratitis among infectious keratitis has a long course, poor recovery and easy recurrence. The disease often has obvious irritation symptoms, such as photophobia, tearing, soreness, etc. Patients often complain of blurred vision, which is often accompanied by uveal reactions, and even iridocyclitis, anterior chamber abscess, or secondary glaucoma. It is one of the more common blinding eye diseases in clinical practice. In the early stage of fungal keratitis, hyphae grow horizontally in the cornea. In severe cases, they can penetrate the posterior Descemet's membrane of the cornea and enter the eye. The eye may experience obvious foreign body sensation or stinging, blurred vision and other symptoms, accompanied by a small amount of secretions. There are bulges at the corneal lesions, and serious signs such as endothelial plaques, immune rings, and hypopyon. The clinical symptoms of bacterial keratitis are photophobia, tearing, pain, blepharospasm, and visual impairment in the affected eye. As the disease progresses, the infiltration focus expands rapidly, followed by the formation of ulcers. The ulcer surface and conjunctival sac often have purulent secretions, and complications such as iridocyclitis, corneal perforation, and corneal fistula may occur.
[0003] At present, the treatment of infectious corneal diseases is mainly based on the principle of inhibiting the reproduction of pathogens and relieving inflammatory irritation to the eyes. Patients can take antiviral or antibacterial drugs, as well as anti-inflammatory and analgesic drugs to treat infectious corneal diseases. Severe infectious corneal diseases usually require corneal transplantation. The drugs currently used to treat infectious corneal diseases mainly target inflammatory factors and do not have the function of restoring the function and characteristics of the corneal epithelium. Therefore, it is of great significance to find therapeutic drugs that can effectively inhibit the immune response caused by pathogenic microorganisms and restore the function and characteristics of the corneal epithelium for the clinical treatment of infectious corneal diseases. Summary of the invention
[0004] The purpose of the present invention is to overcome the shortcomings of the prior art and to use YAP / TAZ inhibitor-2, a drug for treating infectious corneal diseases, in the preparation of drugs for preventing and / or treating corneal diseases caused by pathogenic microorganism infection, which can effectively inhibit the immune response caused by pathogenic microorganism infection and restore the function and characteristics of the corneal epithelium.
[0005] To achieve the above object, the technical solution adopted by the present invention is:
[0006] In a first aspect, the present invention provides the use of YAP / TAZ inhibitor-2 and / or its derivatives in the preparation of drugs for preventing and / or treating corneal diseases caused by pathogenic microorganism infection; the chemical structure of the YAP / TAZ inhibitor-2 is shown as follows:
[0007]
[0008] The present invention first discovered that YAP / TAZ inhibitor-2 can effectively resist corneal damage caused by DI at the cell experiment level and animal experiment level. Cell experiments found that YAP / TAZ inhibitor-2 can activate the expression of corneal epithelial cell characteristic genes and promote corneal epithelial cell differentiation; animal experiments found that YAP / TAZ inhibitor-2 can effectively alleviate corneal epithelial cell lesions, maintain corneal transparency and integrity, and restore corneal characteristics and physiological functions to normal.
[0009] As a preferred embodiment of the application of the present invention, the YAP / TAZ inhibitor-2 derivative is at least one of a pharmaceutically acceptable salt and a stereoisomer of YAP / TAZ inhibitor-2.
[0010] In a second aspect, the present invention provides the use of YAP / TAZ inhibitor-2 combined with an anti-corneal damage drug in the preparation of a drug for preventing and / or treating corneal diseases caused by infection with pathogenic microorganisms.
[0011] As a preferred embodiment of the application of the present invention, the anti-corneal damage drug includes at least one of a flute family compound, a photosensitizer, an integrin, an antioxidant, an interferon, a xanthocyanin derivative, a growth hormone, a neurotrophic factor, a neovascularization regulator, an anti-VEGF antibody, a prostaglandin, an antibiotic, a phytoestrogen, an anti-inflammatory compound and an anti-angiogenic compound.
[0012] In a third aspect, the present invention provides the use of YAP / TAZ inhibitor-2 in combination with anti-inflammatory drugs and / or anti-pathogenic microorganism drugs in the preparation of drugs for preventing and / or treating corneal diseases caused by pathogenic microorganism infection.
[0013] As a preferred embodiment of the application of the present invention, the corneal disease caused by pathogenic microorganism infection is a corneal epithelial cell damage disease caused by pathogenic microorganism infection.
[0014] As a preferred embodiment of the application of the present invention, the corneal diseases caused by infection with pathogenic microorganisms include at least one of herpes simplex keratitis, vaccinia keratitis, herpes zoster keratitis, filamentous keratitis, Fusarium and Aspergillus fungal keratitis, Staphylococcus aureus keratitis, Escherichia coli keratitis, Streptococcus keratitis, Pseudomonas aeruginosa keratitis, Haemophilus influenzae keratitis, Neisseria gonorrhoeae keratitis, corneal ulcer and corneal perforation.
[0015] As a preferred embodiment of the use of the present invention, the effective dose of the YAP / TAZ inhibitor-2 is 10-100 μg of YAP / TAZ inhibitor-2 per 1 kg body weight of the organism.
[0016] As a preferred embodiment of the use of the present invention, the effective dose of the YAP / TAZ inhibitor-2 is 25-80 μg of YAP / TAZ inhibitor-2 per 1 kg body weight of the organism.
[0017] In a fourth aspect, the present invention provides a drug for preventing and / or treating infectious corneal diseases, comprising at least one of the above-mentioned YAP / TAZ inhibitor-2 and / or its derivatives, anti-corneal damage drugs, anti-inflammatory drugs and anti-pathogenic microorganism drugs; the drug for preventing and / or treating infectious corneal diseases also includes a pharmaceutically acceptable carrier.
[0018] As a preferred embodiment of the drug of the present invention, the dosage form of the drug for infectious corneal diseases includes at least one of tablets, solutions, suspensions, emulsions, microcapsules, microspheres, injections, liposomes and aerosols.
[0019] Compared with the prior art, the present invention has the following beneficial effects:
[0020] 1. The present invention first discovered that YAP / TAZ inhibitor-2 can effectively resist corneal damage caused by DI at the cell experiment level and animal experiment level. Cell experiments found that YAP / TAZ inhibitor-2 can activate the expression of corneal epithelial cell characteristic genes and promote corneal epithelial cell differentiation; animal experiments found that YAP / TAZ inhibitor-2 can effectively alleviate corneal epithelial cell lesions, maintain corneal transparency and integrity, and restore corneal characteristics and physiological functions to normal.
[0021] 2. The present invention found that YAP / TAZ inhibitor-2 has high efficacy and no obvious drug toxicity, and can become a strong and effective target drug for the clinical treatment of infectious corneal diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0022] Figure 1The statistical results of the expression levels of corneal epithelial markers detected by qRT-PCR technology in each treatment group in Experimental Example 1 of the present invention;
[0023] Figure 2 The statistical results of the qRT-PCR detection of the gene expression levels of inflammatory factors in the negative control group and the model control group in Experimental Example 1 of the present invention;
[0024] Figure 3 The results of the analysis of the gene expression levels of the STING pathway corresponding to the model control group in Experimental Example 2 of the present invention in the high-throughput sequencing;
[0025] Figure 4 The statistical results of the expression levels of pro-inflammatory factors detected by qRT-PCR technology in the negative control group and the model control group in Experimental Example 2 of the present invention;
[0026] Figure 5 The results of eyeball white light and sodium fluorescein staining of mice in each treatment group in Experimental Example 2 of the present invention;
[0027] Figure 6 These are the HE staining results of the internal organs of mice in each treatment group in Experimental Example 3 of the present invention. DETAILED DESCRIPTION
[0028] In order to better illustrate the purpose, technical solutions and advantages of the present invention, the present invention will be further described below in conjunction with specific embodiments.
[0029] Unless otherwise specified, the reagents and consumables used in the following experimental examples can be obtained through commercial channels.
[0030] YAP / TAZ inhibitor-2 was purchased from MCE with the catalog number HY-112921B.
[0031] The human corneal tissues in the following experimental examples were derived from the Eye Bank of Zhongshan Daxue Zhongshan Eye Center and have been reviewed by the Clinical Ethics Committee with the ethics number 2023KPYJ126.
[0032] The cGAMP analog diABZI STING agonist-1trihydrochloride (DI) in the following experimental example was purchased from MCE, with the catalog number HY-112921B. DI is a cGAMP analog. Studies have reported that cGAS (Cyclic GMP-AMP Synthase), as an important DNA receptor in cells, is activated by the genomes of viruses, bacteria and fungi, promoting the synthesis of the second messenger cGAMP (Cyclic GMP-AMP) and further activating STING (Stimulator of interferon gene stimulator protein). Genes), which eventually induce the production of type I interferon, thereby resisting infection by foreign pathogens or triggering autoinflammatory responses. It is an important component of the body's innate immune signal. As an immune-privileged tissue, the cornea will activate the cGAS-STING immune pathway when invaded by pathogenic microorganisms, inducing a strong inflammatory response. Sustained immune and inflammatory responses will damage the corneal epithelium, leading to abnormal differentiation of corneal epithelial cells and loss of characteristic gene expression, thereby destroying corneal homeostasis and causing corneal loss of transparency. It is one of the causes of a series of blinding diseases such as corneal ulcers and perforations. DI can directly bind to and induce the phosphorylation of STING, thereby activating STING and its downstream inflammatory response, and has been widely used to simulate immune responses and cellular responses caused by microbial infections.
[0033] The differentiation medium used in the following experimental examples was purchased from Gibco, catalog number 10744019.
[0034] The sulfobutyl ether β-cyclodextrin (SEB-β-CD) in the following experimental examples was purchased from MCE Company with the product number HY-17031.
[0035] The biological experiments mentioned in the following experimental examples can be performed according to the experimental contents mentioned in "High-throughput Sequencing Technology", "Molecular Biology Experiments" and "Cell Biology Experiments".
[0036] Experimental Example 1
[0037] In order to verify the repair effect of YAP / TAZ inhibitor-2 on DI-induced inflammatory damage to corneal epithelial cells in vitro, the specific scheme is as follows:
[0038] 1 Experimental materials and treatment
[0039] 1.1 Human corneal limbal tissue was selected as the experimental object. The human corneal limbal tissue was washed with DMEM, chopped and enzymatically hydrolyzed, and then planted in a 12-well plate covered with 10wt% Matrigel at 37℃ and 5% CO2, and the medium was changed every other day;
[0040] 1.2 After the primary corneal limbal stem cells have grown fully, they are digested with 0.25% trypsin-EDTA, and the resuspended cells are seeded in a 12-well plate covered with 10wt% Matrigel and cultured at 37°C with 5% CO2 and the medium is changed every other day;
[0041] 1.3 After the cells have grown completely, remove the limbal stem cell culture medium and wash once with PBS to remove the blood remaining on the cell surface;
[0042] 1.4 The limbal stem cells were induced to differentiate using differentiation medium and cultured continuously for 7 days at 37°C and 5% CO2. The medium was changed every day and the cell status was observed to obtain high-purity corneal epithelial cells. Unless otherwise specified, the culture conditions of the obtained corneal epithelial cells were 37°C and 5% CO2.
[0043] 2. Preparation of reagents
[0044] 2.1 Dissolve DI in DMSO to prepare a 50 mM stock solution for later use; dissolve YAP / TAZ inhibitor-2 in DMSO to prepare a 50 mM stock solution for later use;
[0045] 2.2 The DI mother solution and YAP / TAZ inhibitor-2 mother solution obtained in step 2.1 were diluted with culture medium to 10 μM DI working solution and 10 μM YAP / TAZ inhibitor-2 working solution, respectively.
[0046] 3 Experimental content
[0047] Three treatment groups were set up, namely the negative control group (DMSO group), the model control group (DI group) and the experimental group (DI+YAP / TAZ inhibitor-2). The corneal epithelial cells obtained in step 1.4 were treated according to the above grouping, and the cells were cultured for 3 days to observe the cell changes and detect the expression of corneal epithelial cell-related protein markers (KRT3, KRT24, CLU, ALDH3A1) and inflammation-related genes (CSF3, FGF2, ICAM1, IRAK2, IRAK3, JAK2, TIMP1, interleukin family) by qRT-PCR technology. The primers used for qRT-PCR are shown in Table 1, and the results are shown in Figure 1-2 .
[0048] Table 1 qPCR primers
[0049]
[0050]
[0051] like Figure 1-2As shown in the figure, compared with the negative control group, after DI treatment of corneal epithelial cells for 72 hours, the gene expression of corneal epithelial markers KRT3, KRT24, CLU, and ALDH3A1 was significantly downregulated, while the expression of inflammatory factor genes (including CSF3, FGF2, ICAM1, IRAK2, IRAK3, JAK2, TIMP1, and interleukin family) was significantly increased, indicating that DI can induce inflammatory damage to corneal epithelial cells, and the model was successfully established in this experiment. The expression level of corneal epithelial markers in the DI+YAP / TAZ inhibitor-2 co-treatment group was close to or higher than that of the negative control group, and the expression level of inflammatory factor genes was lower than that of the model control group, indicating that YAP / TAZ inhibitor-2 can significantly improve cell inflammatory damage caused by DI, restore cell status, activate the expression of corneal epithelial cell characteristic genes, and restore the function and characteristics of corneal epithelial cells.
[0052] Experimental Example 2
[0053] In order to verify the effect of YAP / TAZ inhibitor-2 on DI-induced corneal epithelial cell inflammatory damage in vivo, the specific protocol is as follows:
[0054] 1 Animal Grouping
[0055] The experimental subjects were 4-6 week old male C57 / BL6 mice. Three treatment groups were set up in this experiment, namely the negative control group CTR (20wt% SBE-β-CD solution), the model control group (DI) and the experimental group (DI+YAP / TAZ inhibitor-2).
[0056] 2. Reagent preparation
[0057] The DI mother solution obtained in step 2.1 of Experimental Example 1 was dissolved in a 20wt% SBE-β-CD solution, and the concentration was 100 μg / kg calculated according to the animal weight; the YAP / TAZ inhibitor-2 mother solution obtained in step 2.1 of Experimental Example 1 was dissolved in a 20wt% SBE-β-CD solution, and the concentration was 40 μg / kg calculated according to the animal weight.
[0058] 3 Experimental content
[0059] According to the grouping described in step 1, the mice were injected with reagents into the cornea and conjunctiva, and the eyeballs were stained with white light and fluorescein sodium and photographed on days 0, 3, 5, 7 and 10 after injection; the mice were killed by cervical dislocation on the 10th day after injection, and tissue paraffin sections were made from some eyeballs for qPCR expression detection (NFKB1, NFKB2, RELB, JAK2, CXCL1, CXCL2, CXCL3, CXCL4, IL1A, IL1B, IL2RA, IL4RA and IL10); corneal tissue was cut from some eyeballs to extract RNA for high-throughput sequencing. The above detection method is referenced to: dsRNA Induced IFNβ-MMP13 Axis Drives Corneal WoundHealing. Invest Ophthalmol Vis Sci. 2022Feb 1; 63(2):14. The primers used for qPCR detection are shown in Table 2, and the results of high-throughput sequencing are shown in Figure 3 , qPCR results are shown in Figure 4 , the results of eyeball white light and sodium fluorescein staining are shown in Figure 5 .
[0060] Table 2 Primers and sequences used in qPCR
[0061]
[0062]
[0063] like Figure 3 As shown in the figure, GO analysis showed that after the STING pathway in the cornea of the model control group mice was activated, the changes in genes caused were enriched in biological processes related to inflammatory response and immune response. The horizontal axis represents the significance test value, and the vertical axis represents the enriched GO term; Figure 4 As shown in Figure 2, a large number of pro-inflammatory factors (including NF-κB, JAK2, chemokine family and interleukin family) were activated in the corneal epithelium of mice in the model control group; Figure 5 As shown, the corneal epithelium of mice in the model control group was significantly damaged, and the damaged area increased with time. The above data indicate that injection of DI can successfully construct a corneal disease model caused by pathogenic microorganisms.
[0064] like Figure 4-5 As shown, the expression level of pro-inflammatory factors in the corneal epithelium of mice treated with YAP / TAZ inhibitor-2 decreased, the damage caused by DI was alleviated, and the recovery effect became better with time, indicating that YAP / TAZ inhibitor-2 can improve the corneal epithelial damage caused by the inflammatory response caused by DI, maintain the integrity and transparency of the corneal epithelium, and restore the physiological function of the corneal epithelium to normal.
[0065] Experimental Example 3
[0066] In order to verify the safety of YAP / TAZ inhibitor-2, the internal organs of mice in the three treatment groups set in Experimental Example 2 were observed by HE staining. The specific scheme is as follows:
[0067] The experimental scheme was similar to that of Experimental Example 2, except that the three treatment groups were negative control group CTR (20 wt% SBE-β-CD solution), experimental group 1 (YAP / TAZ inhibitor-2) and experimental group 2 (DI+YAP / TAZ inhibitor-2), and the other steps and parameters remained unchanged.
[0068] The mice in the three treatment groups were killed by cervical dislocation on the 10th day after injection, and the hearts, livers, kidneys and lungs were removed by dissection. Paraffin sections and HE staining were performed. The results are shown in Figure 6 .
[0069] like Figure 6 As shown, whether the mice were injected with YAP / TAZ inhibitor-2 alone or DI+YAP / TAZ inhibitor-2 at the same time, the heart, liver, kidney and lung tissues of the mice were normal, and no obvious drug toxicity was observed, indicating that YAP / TAZ inhibitor-2 has good drug safety.
[0070] Finally, it should be noted that the above embodiments are only used to illustrate the technical solution of the present invention rather than to limit the scope of protection of the present invention. Although the present invention has been described in detail with reference to the preferred embodiments, those skilled in the art should understand that the technical solution of the present invention can be modified or replaced by equivalents without departing from the essence and scope of the technical solution of the present invention.
Claims
1. Use of YAP / TAZ inhibitor-2 and / or its pharmaceutically acceptable salt in the preparation of a drug for preventing and / or treating corneal diseases caused by pathogenic microorganism infection; the chemical structure of the YAP / TAZ inhibitor-2 is shown below: 。 2. The use according to claim 1, characterized in that The corneal disease caused by pathogenic microorganism infection is a corneal epithelial cell damage disease caused by pathogenic microorganism infection.
3. The use according to claim 2, characterized in that The corneal diseases caused by infection with pathogenic microorganisms include at least one of herpes simplex keratitis, vaccinia keratitis, herpes zoster keratitis, filamentous keratitis, Fusarium and Aspergillus fungal keratitis, Staphylococcus aureus keratitis, Escherichia coli keratitis, Streptococcus keratitis, Pseudomonas aeruginosa keratitis, Haemophilus influenzae keratitis, Neisseria gonorrhoeae keratitis, corneal ulcer and corneal perforation.
Citation Information
Patent Citations
Substituted pyrazolopyrimidines, a process for their preparation and their use as medicine
CN101501036A
Pyrazole naphthylurea tyrosine kinase inhibitor and its application
CN103214479A
